Immune checkpoint inhibitors have achieved remarkable progress in tumor treatment, and two vital checkpoint receptors, CTLA-4 and the programmed death-1 receptor (PD-1), have been studied most extensively in clinical cancer immunotherapy [3, 4]. Here, CTLA4 is linked to cancer.